Nicos Peciardis | Lightrocket | Getty images
Fizer Monday said that it will end its experimental development Daily weight loss pill A patient was probably caused by the drug in a test after experiencing a liver injury.
In a statement, the patient did not experience any liver -related symptoms or side effects, a fizzle spokesman said in a statement. He said that after the patient’s liver enzyme “recovered rapidly”, he stopped taking the bullet, which is an oral GLP -1 drug called Denuglipron. The statement shows that the patient’s liver enzymes were elevated, which is often Indicates damage to cells There is more in the limb One issue It is associated with some other obesity drugs.
The spokesman said the matter took place in a test, which quickly extended the bullet dose. Physician decision to prevent the development of the drug came after reviewing the totality of information, which includes inputs from all clinical data and regulators to Denglipron, according to a release, “according to a release.
The Chief Scientific Officer of Fizer, Dr. “While we are disappointed to stop the development of Denuglipron, we are committed to evaluating and moving forward in an attempt to bring innovative new drugs to patients,” Chris Bosoff said. He said that the company is still developing other weight loss medicines.
The announcement adds a string of failures to the company’s bid to win a rapidly growing market for GLP-1s, which mimics some intestine hormones to reduce appetite and regulate blood sugar. Fizer is one of several drug manufacturers racing to bring a more convenient weight loss drug to a place dominated by the weekly injection, but it is behind the contestants. Ellie lily And Novo nordisk,
Some Wall Street analysts hope that the GLP-1 industry will be more than $ 150 billion in the early 2030s. Oral GLP-1s may be priced at $ 50 billion of that total, while injections will be responsible for the rest Some analyst estimates,
This is not back of the first set of the fugger with Denglipron, especially, either. Company Close In December 2023, twice the daily version of the tablet, patients had trouble tolerating the drug in a mid -stage study.
But the Physician back in July appeared to be confident in Danuglipron once, when it was said Start studying In the second half of the year to evaluate several doses of the pill.
Despite its decision to scrap the drug, Fizer said on Monday that those studies met the major goals and confirmed a certain form of the pellet with the ability to give “competitive efficacy and tolerance” in late stages tests.
The company also noted that the rate of Liver enzyme The GLP-1 approved in people taking Danuglipron is based on drugs, which is based on the safety database of more than 1,400 patients who have taken PFIZER pill.
Fizer separated a one-time-world obesity tablet once in June 2023, when patients taking that drug had high liver enzyme levels in a mid-stage testing. Investors have been pessimistic about the company’s ability in GLP-1 space.
Still, the fugger is Other practical Obese drugs are in its pipeline in the early stages of development, which now work differently from its-systematic treatments. It contains an oral drug that blocks another intestine hormone called GIPR, which enters the two tests phase two last year, and phase one test at a time-diner oral GLP-1.
Fizer believes that a drug targeting GIPR can be more effective and easy to bear patients, former Chief Scientific Officer Mikel Dolstein, who left the company, told investors in October. He said that “there are lots of applications for GLP-1s.”
Danuglipron of Fizer promoted weight loss by targeting GLP -1, which is also how Novo Nordisk’s weight loss injection vegovi and diabetes treatment are ozmpic work. Elli Lily’s weight loss injection Jeepbounds and diabetes targeted the mounzaro, but also activated another intestine hormone called GIP.
The only oral GLP-1 Novo Nordiskis approved by the Food and Drug Administration is the Raybelus of Novo Nordisk, which treats Type 2 diabetes and has been recorded for about $ 3.38 billion. Sales In 2024.
The announcement of the Fizer comes on Monday because the company withdraws its feet and Its share price is cured After the rapid decline of its covid business. Fizer is betting on its pipeline of cancer drugs to give long -term development, but emphasized that obesity is a significant attention.
